Pay in 4 interest-free payments of $6.94 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
SUMOUNT-4 demonstrated that continued treatment is necessary to maintain weight loss, with significant regain occurring after discontinuation
As per an article published by the Canadian Health Policy Journal in April 2026, the most-favored-nation (MFN) reference-specific drug pricing policy was launched by the government, demanding brand medicines without competitors to be set at the lowest pricing strategy, with a GDP per capita of nearly 60%
Superior Blood Sugar Control In head-to-head trials, tirzepatide reduced HbA1c by up to 2.6% compared to semaglutide's 1.9%
Innovation is part of our DNA at Evernorth, and we will continue advancing new solutions to make health care better for all. The EnReachRx suite of solutions will be available beginning in June 2025
US$ 27.51
US$ 20.96
US$ 26.40
US$ 27.27
US$ 26.63
US$ 21.49
US$ 20.59
US$ 25.60
